Metastasis of colorectal cancer (CRC) to the central nervous system (CNS) is relatively rare but leads to shorter survival of these patients (pts) even with improvement of palliative treatments. The aim of this study was to evaluate the epidemiological profile and the prognostic factors of pts with CRCBM. We evaluated pts with metastatic CRC and CNS involvement treated from Jan 2002 to Aug 2020 in a single cancer center institution. We used summary statistics to describe the population. Overall survival (OS) was calculated according to the Kaplan-Meier method. We performed univariate analysis to evaluate potential prognostics factors for OS using SPSS software version 24. We identified 46 pts with a median age of 63,9 years (39,3 - 86,3), 50% were male and 80% have good performance status (ECOG 0-1). The predominant primary side was the left side (71,7%). 60,5% were stage IV, 71,7% previously presented lung metastasis and 76,7% had a high volume of lung disease (2 or more nodes). No MSI-High or BRAF mutations were detected. RAS mutation was detected in 56,5% of the pts. In the first line, the most used chemotherapy (CT) regimen was oxaliplatin doublet (51,1%), with disease control in 83,7% of cases. 68,3% presented lung progression to the first line. FOLFIRI was used in 53,5% in the second line. Overall, 65,2% used anti-VEGF. Progression to CNS occurred after a median of 3 treatment lines, the median time between diagnosis and progression to CNS was 49,5 months, 33 months after the first-line treatment and 19,3 months after lung metastasis. The median CEA at CNS metastasis was 45. Headache (26,7%) and motor alterations (24,4%) were the most common symptoms but 15,6% of the patients were asymptomatic. 60,9% had supratentorial nodes and 55,6% had just one lesion, with 24mm median size. After a median follow up time of 27,2 months, the OS was 6,4 months (1.6 to 11,1). The use of anti-EGFR therapy and the RAS mutation had no impact on survival (p> 0.2). 32,6% underwent brain metastasis resection (HR 0,25; p < 0,01; 95% CI 0,09 - 0,68) and 65,2% received CNS radiation (HR 0,2; p < 0,01; 95% CI 0,08 - 0,51). This study found that most patients with CNS metastasis were ECOG 0 or 1, had CNS progression after 3 lines of palliative treatment, had previous high volume lung metastasis, and had left-sided tumors. 15,6% were asymptomatic, the median time between diagnosis and progression to CNS was over 4 years (49,5 months), 33 months from the start of palliative treatment and more than 19 months from lung metastasis. Colorectal patients with this profile should be systematically screened for CNS metastasis once treating CNS metastasis decreases mortality. Our findings must be validated with a larger cohort of patients.